NCT03045887View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

August 11, 2017

Study Completion Date

August 16, 2017

Conditions
Asthma
Interventions
DRUG

GSK2292767 50 μg

GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation

DRUG

GSK2292767 500 μg

GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation

DRUG

Placebo

Lactose as powder for inhalation

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03045887 - Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes | Biotech Hunter | Biotech Hunter